HonCode

Go Back   HER2 Support Group Forums > Inflammatory Breast Cancer
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 05-26-2010, 08:56 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,757
another new IBC review article--this time from MD Anderson

new article in terms of publishing--but was presented in Dec 2008 @ first IBC conference

http://www3.interscience.wiley.com/c...7246/HTMLSTART
Supplement
Novel targeted therapies in inflammatory breast cancer
Massimo Cristofanilli, MD * a
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
email: Massimo Cristofanilli (mcristof@mdanderson.org)
*Correspondence to Massimo Cristofanilli, Department of Breast Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030

aCurrent address: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

The articles in this supplement were presented at the First International Inflammatory Breast Cancer Conference, Houston, Texas, December 5-7, 2008.
Fax: (713) 794-4385
KEYWORDS
inflammatory breast cancer • chemotherapy • HER2 • trastuzumab • lapatinib
ABSTRACT

Inflammatory breast cancer (IBC) accounts for 1% to 5% of all breast cancer cases. Its aggressive biology is characterized by rapid disease progression and poor prognosis. To improve and standardize therapy for IBC, development of novel therapeutics to molecular targets of IBC is key. Trastuzumab treatment, an anti-HER2 humanized monoclonal antibody, has been demonstrated to improve the 3-year survival rate of patients with IBC (70.1% vs 53.3%; P = .0007). Another chemotherapeutic drug, lapatinib, a dual tyrosine inhibitor of epidermal growth factor (EGFR) and HER2 signaling, in combination with capecitabine demonstrated encouraging results, with a 51% decrease in disease progression. Further investigation is needed to confirm the efficacy of lapatinib. Cancer 2010;116(11 suppl):2837-9. 2010 American Cancer Society.
Lani is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 04:28 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter